- Trials with a EudraCT protocol (345)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
345 result(s) found for: Manual therapy.
Displaying page 1 of 18.
EudraCT Number: 2013-005384-66 | Sponsor Protocol Number: AUX-CC-807 | Start Date*: 2014-04-28 |
Sponsor Name:Endo Ventures Limited | ||
Full Title: A phase 3b, open-label pilot study to evaluate the safety and effectiveness of up to four treatment cycles of AA4500 in combination with the ErecAid® Esteem® Manual Vacuum Therapy System in men wit... | ||
Medical condition: Peyronie's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003913-32 | Sponsor Protocol Number: HeLeNe-18-02 | Start Date*: 2020-11-18 |
Sponsor Name:Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital | ||
Full Title: Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without ... | ||
Medical condition: acute myeloid leukemia (AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000525-25 | Sponsor Protocol Number: 61186372NSC3004 | Start Date*: 2022-09-05 | |||||||||||
Sponsor Name:JANSSEN CILAG INTERNATIONAL NV | |||||||||||||
Full Title: A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous on Body Deliv... | |||||||||||||
Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001497-29 | Sponsor Protocol Number: RA101495-02.202 | Start Date*: 2019-10-17 | |||||||||||
Sponsor Name:Ra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy | |||||||||||||
Medical condition: Immune-Mediated Necrotizing Myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004371-12 | Sponsor Protocol Number: U31287-A-U301 | Start Date*: 2014-08-04 | |||||||||||
Sponsor Name:Daiichi Sankyo Development Limited | |||||||||||||
Full Title: Phase 3, Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wild-type Subjects with Locally Advanced or Metasta... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) DE (Prematurely Ended) HU (Completed) ES (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000246-30 | Sponsor Protocol Number: FERINJECT | Start Date*: 2014-09-30 | ||||||||||||||||
Sponsor Name:IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest gGmbH | ||||||||||||||||||
Full Title: Intravenous ferric carboxymaltose vs. oral iron substitution in patients with metastatic colorectal cancer (CRC) and iron deficiency anemia: a randomized multicenter treatment optimization study. | ||||||||||||||||||
Medical condition: Iron deficiency anemia in patients with metastatic or inoperable colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002767-30 | Sponsor Protocol Number: ACT17453 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & developpement | |||||||||||||
Full Title: A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory ... | |||||||||||||
Medical condition: Relapsed/refractory multiple myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003799-33 | Sponsor Protocol Number: IgPro20_4004 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: An open-label multicenter study to evaluate the safety and tolerability of higher infusion parameters of immune globulin subcutaneous (human), 20% liquid (Hizentra®) in subjects with primary immuno... | |||||||||||||
Medical condition: Primary immunodeficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000317-36 | Sponsor Protocol Number: 0646-025 | Start Date*: 2012-06-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Can... | |||||||||||||
Medical condition: rectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) GB (Completed) BE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000755-40 | Sponsor Protocol Number: ATB200-03 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Algluc... | |||||||||||||
Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) SE (Completed) HU (Completed) BE (Completed) SK (Completed) ES (Completed) NL (Completed) BG (Prematurely Ended) SI (Completed) GR (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000663-26 | Sponsor Protocol Number: MD-NET R17 | Start Date*: 2005-04-25 |
Sponsor Name:Universitätsklinik Freiburg | ||
Full Title: Immunsuppressive Therapy in Duchenne Muscular Dystrophy | ||
Medical condition: Duchenne Muscular Dystrophy | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004283-23 | Sponsor Protocol Number: Emboli Inhibition | Start Date*: 2006-05-05 |
Sponsor Name:South Manchester University Hospital | ||
Full Title: An evaluation of potential therapies to inhibit cerebral emboli in dementia | ||
Medical condition: Alzheimer's Disease and Vascular Dementia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005596-39 | Sponsor Protocol Number: MPELONG | Start Date*: 2022-09-07 |
Sponsor Name:MAPS Europe B.V. | ||
Full Title: Long-Term Safety and Persistence of Effectiveness of Manualized MDMA Assisted Therapy for the Treatment of Posttraumatic Stress Disorder | ||
Medical condition: post-traumatic stress disorder (PTSD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000954-67 | Sponsor Protocol Number: ATB200-07 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease | |||||||||||||
Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) DK (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) SI (Trial now transitioned) AT (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003739-22 | Sponsor Protocol Number: GAL-01-2007 | Start Date*: 2007-10-04 | |||||||||||
Sponsor Name:GALSOR S.R.L. | |||||||||||||
Full Title: Safety and efficacy (for the symptom remission) of the treatment adjuvant of the antibiotic therapy of the acute episode of sinusitis (acute, subacute, chronic)with Ecballium Elaterium (SINUclean D... | |||||||||||||
Medical condition: Acute sinusitis or exacerbation of subacute or chronic sinusitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003915-30 | Sponsor Protocol Number: MT4VLU07/A-V7 | Start Date*: 2008-05-15 |
Sponsor Name:Gloucestershire Hospitals NHS Foundation Trust | ||
Full Title: The efficacy of maggots as a debridement agent for venous leg ulcers | ||
Medical condition: The purpose of the trial is to evaluate the effectiveness of BioFOAM maggots in achieving rapid debridement of chronic venous leg ulcers. Removal of slough and necrotic tissue from these wounds is ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001097-15 | Sponsor Protocol Number: M15-889 | Start Date*: 2016-09-28 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (Venice II) | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001723-10 | Sponsor Protocol Number: 767905/012 | Start Date*: 2005-08-26 |
Sponsor Name:GlaxoSmithKline R & D Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of O... | ||
Medical condition: Opioid-induced bowel dysfunction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) FI (Completed) GB (Completed) DE (Completed) DK (Completed) EE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003342-15 | Sponsor Protocol Number: F1D-MC-HGMT | Start Date*: 2007-12-05 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) FR (Completed) GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001725-28 | Sponsor Protocol Number: 767905/014 | Start Date*: 2005-08-26 |
Sponsor Name:GlaxoSmithKline R & D Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dys... | ||
Medical condition: Opioid-induced bowel dysfunction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) FI (Completed) SE (Completed) GB (Completed) HU (Completed) AT (Completed) DK (Completed) PT (Completed) ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
